Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BAXTER INTERNATIONAL INCBAX · Entity 1707 | Director | May 05, 2026 | May 07, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BAXTER INTERNATIONAL INC
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, $1 par valueSEC Table I · non-derivative | Direct | 37,076 |
Reported balance
After 2026-05-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 12,836 · Balance 37,076 F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2: Total includes the automatic reinvestment of dividends. |
Filing footnotes · ownership attribution and instrument terms
F1: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant.
F2: Total includes the automatic reinvestment of dividends.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Syneos Health, Inc.
Report date September 28, 2023 · Filed September 28, 2023
Section 16 reporting ended · disclosed 2023-09-28. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2023-09-28 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-09-28 · Disposition to issuer · Disposed 4,973 · Balance 4,863 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Row 2 · 2023-09-28 · Disposition to issuer · Disposed 4,863 · Balance 0 F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes.
F2: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals,
F3: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 05, 2026 Filed May 7, 2026 20:22 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 12,836 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-032196 · wk-form4_1778185337.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,076 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| May 06, 2025 Filed May 8, 2025 20:29 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 7,183 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-25-008905 · form4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,906 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| May 07, 2024 Filed May 9, 2024 20:36 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 5,952 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-24-009789 · form4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 16,274 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. F2 · balance_after: Total includes the automatic reinvestment of dividends. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 17:08 UTC | Syneos Health, Inc. SYNH · Entity 109360 | Disposition to issuerClass A Common Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050776 · doc4.xml · nonDerivative · entry 2 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. F2 · price: In accordance with the Merger Agreement, effective as of immediately prior to the effective time of the Merger (the "Effective Time") and as a result of the Merger each award of restricted stock units ("RSUs") and performance stock units ("PSUs") covering shares of common stock that is outstanding immediately prior to the Effective Time (other than certain specified RSU awards and PSU awards set forth in the disclosure schedules delivered in connection with the Merger Agreement (the "Specified Awards")) was cancelled and converted into a contingent right to receive an amount in cash (without interest) (a "Contingent Cash Award") equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award (with any performance based goals with respect to the PSU awards deemed to be achieved at the "target" level of performance or based on the actual level of achievement of performance goals, F3 · price: continued from previous footnote: in each case, as set forth in the applicable PSU award agreement). Each Contingent Cash Award will vest and become payable pursuant to the same time-vesting schedule applicable to the underlying RSU award or PSU award from which it was converted, as applicable (including any accelerated vesting terms and conditions), subject to the holder's continued employment with or service to Parent and its subsidiaries through the applicable vesting date; and each Specified Award that is outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest) equal to the product of (i) the Merger Consideration and (ii) the aggregate number of shares of common stock subject to the award, subject to claw-back if the holder's employment is terminated by the Company for "cause" or by the holder without "good reason," in either case prior to the first anniversary of the Effective Time. Read SEC document |
| September 28, 2023 Filed Sep 28, 2023 17:08 UTC | Syneos Health, Inc. SYNH · Entity 109360 | Disposition to issuerClass A Common Stock | 4,973 | $43.00 | $213,839.00 |
DisclosureSEC source: 0001209191-23-050776 · doc4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,863 F1 · price: Reflects disposition in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated as of May 10, 2023 (the "Merger Agreement"), by and among Syneos Health, Inc. (the "Issuer"), Star Parent, Inc. ("Parent") and Star Merger Sub, Inc. ("Merger Sub"). On September 28, 2023, upon the closing of the merger of Merger Sub with and into the Issuer (the "Merger") contemplated by the Merger Agreement, each outstanding share of common stock of the Issuer, par value $0.01 per share, was cancelled and automatically converted into the right to receive an amount in cash equal to $43.00 (the "Merger Consideration"), without interest, and minus any applicable withholding taxes. Read SEC document |
| May 25, 2023 Filed May 30, 2023 17:05 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 4,863 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-032928 · doc4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,836 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the 2024 annual meeting of stockholders but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document |
| May 02, 2023 Filed May 4, 2023 20:36 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 4,573 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-23-010217 · form4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,034 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| May 25, 2022 Filed May 27, 2022 17:12 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 2,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-032647 · doc4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,973 F1 · shares: Represents an award of restricted stock units that vests in full one year from the grant date, or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting, in each case, subject to continued service on the Issuer's Board of Directors. Read SEC document |
| May 03, 2022 Filed May 5, 2022 21:27 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 2,706 | $0.00 | $0.00 |
DisclosureSEC source: 0001062993-22-011694 · form4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,339 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| June 15, 2021 Filed Jun 16, 2021 16:37 UTC | Syneos Health, Inc. SYNH · Entity 109360 | GrantClass A Common Stock | 2,134 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-040933 · doc4.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,134 F1 · shares: Represents an award of restricted stock units which vests in full one year from the grant date, subject to continued service on the Issuer's Board of Directors or, if earlier, the date of the next subsequent annual meeting following the grant date but only to the extent the director is not re-elected as a non-employee director at such annual meeting. Read SEC document |
| May 04, 2021 Filed May 6, 2021 22:07 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 2,230 | $0.00 | $0.00 |
DisclosureSEC source: 0001842866-21-000003 · edgar.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,597 F1 · shares: The reporting person received a grant of fully vested shares of common stock of Baxter International Inc., subject to the terms and conditions of the applicable grant. Read SEC document |
| February 16, 2021 Filed Feb 17, 2021 21:10 UTC | BAXTER INTERNATIONAL INC BAX · Entity 1707 | GrantCommon Stock, $1 par value | 366 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001842866-21-000002 · edgar.xml · nonDerivative · entry 1 Wilkes David S. · CIK 0001842866 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 366 F1 · shares: The reporting person received a grant of 366 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant. F1 · price: The reporting person received a grant of 366 fully vested shares of common stock of Baxter International Inc. subject to the terms and conditions of the applicable grant. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.